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Abstract
BACKGROUND: A lot of unresolved questions still exist con-
cerning the exact mechanism of the beneficial effects of bone
marrow cell (BMC) transplantation for myocardial regeneration.
The aim of this communication is to report the cases of patients
with and without post-transplantation left ventricular function
improvement.
MATERIAL AND METHODS: To this study we included conse-
cutive patients with irreversible damage after a first acute
ST-elevation myocardial infarction treated by coronary angio-
plasty with stent implantation. The irreversible damage was iden-
tified by dobutamine echocardiography and confirmed by rest
gated Tc-99m-MIBI gated SPECT and in the majority of patients
by F-18-FDG PET imaging as well. Using 4D-MSPECT software,
we quantified MIBI/FDG uptake and gated SPECT left ventricu-
lar ejection fraction, end-diastolic/end-systolic volumes (LVEF,
EDV/ESV) before BMC therapy and 3 months later.
RESULTS: The results obtained in the initial group of patients
in this study (27 patients in the BMC treated group, 16 patients
in the control group) have been published previously [Eur
J Nucl Med 2005; 32 (Suppl 1 ): S46]. Among the BMC group,
we identified 13 responders to therapy with average LVEF im-
provement from 43.3% – 11% to 51.4% – 10.4% and EDV/ESV
improvement from 145 ml/84 ml to 133 ml/67 ml. The remain-
ing 14 patients were non-responders to therapy with no signif-
icant change in LVEF (39.1% – 8.1% versus 39.8% – 7.4%),
the EDV/ESV increased from 166 ml/105 ml to 188 ml/116 ml.
Responders to the cell therapy had prevailing MIBI uptake
in the range of 3150% of maximum in the infarction territory.
On the other hand, non-responders to BMC therapy had pre-
vailing MIBI uptake in the range of 030% of maximum. Two
cases are presented in this report.
CONCLUSIONS: Further studies with a larger cohort of patients
would be helpful to evaluate our findings. We observed strong
interindividual differences in the effectiveness of the cell therapy.
Prevailing residual MIBI uptake in the range of 3150% of maxi-
mum was in the subgroup of responders to the cell therapy.
Key words: acute myocardial infarction, myocardial viability,
bone marrow cell trans, MIBI SPECT, FDG PET
Introduction
Clinical outcome after myocardial infarction (MI) depends
on the extent of irreversible damaged myocardium. Recent studies
report on a new approach of bone marrow cell (BMC) transplan-
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tation for myocardial regeneration in animal models and in hu-
mans [17]. However, a lot of unresolved questions still exist con-
cerning the exact mechanism of beneficial effects of cell trans-
plantation. Nuclear medicine methods enable the evaluation
of myocardial perfusion, function and metabolism providing well-
-validated diagnostic information on myocardial viability assess-
ment [811]. The aim of this communication is to report the role
of imaging methods used to confirm repair of infarcted myocardi-
um due to BMC transplantation; we analysed the cases of pa-
tients with and without the benefit of this therapy.
Material and methods
We demonstrate cases from our prospective multicentre study.
In November 2003, we started monitoring the effects of intracoro-
nary BMC therapy to determine the impact of the dose of trans-
planted cells on myocardial function and perfusion, and to identi-
fy the potential interindividual differences in the effectiveness
of the cell therapy. The results obtained in the initial patients in this
study have been published previously [12]. To the study we in-
cluded consecutive patients with irreversible damage after a first
acute ST-elevation MI treated by coronary angioplasty with stent
implantation. The irreversible damage was identified by dob-
utamine echocardiography and confirmed by rest gated Tc-99m-
-MIBI gated single-photon emission computed tomography
(SPECT) and in the majority of patients by F-18-fluorodeoxyglu-
cose (FDG) positron emission tomography (PET) imaging as well.
The patients were randomized to two BMC treated groups (lower
and higher cell dose) or to the control group without cell trans-
plantation therapy. The echocardiography, gated rest MIBI SPECT,
and FDG PET were repeated 3 months later. The institutional eth-
ics committee approved the study and written consent was ob-
tained from each patient.
Echocardiography
Echocardiography examinations were performed using Vivid 7
(GE/Vingmed, Milwaukee, Wisconsin, USA) with an M3S trans-
ducer. After resting echocardiography including colour Doppler
tissue imaging, low-dose dobutamine was performed to assess
myocardial viability. Dobutamine was administered with an infu-
sion pump at doses of 5, 10, and 20 ug/kg/min each for 5 mi-
nutes. Parasternal long axis and three apical views were digitally
stored at rest and at the last minute of all doses of dobutamine for
subsequent wall motion analysis. Regional wall motion analysis
was performed using a 16-segment model recommended by the
American Society of Echocardiography [13] and a conventional
scoring system was used (1  normokinesis, 2  hypokinesis,
3  akinesis, 4  dyskinesis) for each segment. The akinetic and
dyskinetic segments with no improvement in thickening after any
dose of dobutamine were regarded as irreversibly damaged.
Gated Tc-99m-MIBI SPECT acquisition
All examinations were performed in one centre using stan-
dard methodology. 740 MBq Tc-99m-MIBI was injected at rest.
Gated single photon emission computed tomography (gated
SPECT) imaging acquisition began 1 hour after MIBI injection using
a 2-detector Siemens e.cam gamma camera (Siemens Medical
Solutions, Erlagen, Germany) equipped with low-energy, high-reso-
lution parallel-hole collimators. Sixty-four projections were acquired
in a 64 × 64 matrix over 180° from the 45° right anterior oblique
projection to the 45° left posterior oblique projection. Ima-
ges were gated at 8 frames per cardiac cycle. Processing was
performed using a Butterworth filter with a frequency cut-off
of 0.45 cycles/pixel and an order of 5.0. No attenuation correction
was used.
F-18-FDG PET Acquisition
F-18-FDG-PET was performed with a whole-body PET scan-
ner ECAT ACCEL (Siemens Medical Solutions, USA) producing
21 continuous tomograms spaced 5.1 mm apart with a slice thick-
ness of 13 mm. To achieve the optimal glucose metabolic situa-
tion, hyperinsulinaemic-euglycaemic clamping was used. Patient
preparation started with the determination of the glucose level.
According to the value measured, a sugar dose of 2550 g was
applied orally. One hour later, the repeat glucose level was deter-
mined and, depending on its level, a dose of insulin in the range
of 14 IU was administered simultaneously with FDG (200
250 MBq intravenously). Acquisition was started 50 minutes af-
ter the administration of FDG and images of glucose utilization
were acquired for 1520 minutes (depending on the patients
weight) in a 3D mode. Transaxial reconstructions were rotated
and displayed in the short axis plane and in the vertical and hori-
zontal long-axis planes.
Gated SPECT and PET data analysis
Images were interpreted visually by a consensus of two expe-
rienced nuclear cardiologists. Each study was interpreted sepa-
rately in a blinded fashion. The extent and severity of perfusion
and metabolism abnormality, gated SPECT rest LV ejection frac-
tions and LV end-diastolic/end-systolic volumes were obtained
through the use of automated, commercially available software
4D-MSPECT (the University of Michigan, Ann Arbor, MI, USA). The
tracer uptake was analysed on computer-generated polar maps.
In perfusion analysis, the polar maps of each patient were com-
pared on a pixel-by-pixel basis with a MIBI normal database de-
rived from 70 normal volunteers. Pixels with a MIBI activity > 2.5 SD
below the corresponding normal mean values were considered
abnormal. Perfusion defect was automatically expressed by the
computer as the number of abnormal pixels divided by the total
number of LV pixels x 100 [8]. Nonviable myocardial area (infarct
size) was expressed as a percentage of the left ventricle with FDG
uptake below 50% having concomitant perfusion SPECT defect
(perfusion-metabolism match area). The superimposition of FDG
and MIBI uptake defects and the quantification of resultant com-
mon defects defining the infarct size were performed automati-
cally by the 4D-MSPECT software.
Implantation of mononuclear bone marrow
cells into the myocardium
Autologous mononuclear bone marrow cells were transplan-
ted via a percutaneous transluminal catheter located in the inf-
arct-related artery using the method described by Strauer et al.
[2]. After insertion of a catheter, the balloon was inflated at the site
of previous angioplasty and stent implantation. Following that,
a total of seven balloon inflations lasting for three minutes were
carried out. Individual inflations were separated by three-minute
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intervals of balloon deflation. At the onset of each balloon inflation
3 ml of mononuclear bone marrow cell suspension was injected
into the infarct-related artery distal to the site of occlusion. This
procedure was performed 5 to 9 days after the onset of MI and
assured direct transport of bone marrow cells into the infarcted
area. Two cell doses were randomly applied: the lower dose
of 1 × 107 cells (LD group) and the higher dose of 1 × 108 cells
(HD group). In both patient groups, the number and duration
of balloon inflations and the cell suspension volume were identical.
Case report 1
42-year-old male, successfully treated by BMC transplanta-
tion (Figure 1). There was evidence of irreversible injury after acute
MI treated by primary angioplasty with stent implantation confirmed
both by dobutamine echocardiography and nuclear imaging. Be-
fore MBC therapy, Tc-99m-MIBI SPECT and F-18-FDG PET im-
ages showed the presence of the perfusion  metabolism match
with both tracers uptake < 50% of maximum. Quantitative analy-
sis using 4D-MSPECT software indicated an extensive nonviable
myocardium (25% of total left ventricle). BMC intracoronary trans-
plantation was performed on post-infarction day 7 (1 × 108 cells).
At 3 months after BMC transplantation, MIBI SPECT and FDG PET
imaging demonstrated improvement in perfusion and metabolism.
Gated SPECT 3D images confirmed post-transplantation improve-
ment in regional wall motion, LVEF (from 45% to 49%), end-dia-
stolic volumes (from 210 ml to 187 ml), and end-systolic volumes
(from 115 ml to 96 ml).
Case report 2
48-year-old male, unsuccessfully treated by BMC therapy (Fi-
gure 2). After acute MI treated by primary angioplasty with stent
implantation, dobutamine echocardiography identified an irrevers-
ible injury, which was confirmed by nuclear imaging. Before BMC
therapy, the images showed very low MIBI and FDG uptake cor-
responding with the perfusion - metabolism match pattern. Quan-
titatively, the extent of nonviable myocardium was 40% of total left
ventricle. On post-infarction day 7, the patient underwent cell in-
tracoronary transplantation (1 × 107 cells). After BMC therapy, the
extent of nonviable myocardium was unchanged (38% of total left
ventricle). Gated SPECT showed no post-transplantation improve-
ment in regional wall motion, LVEF remained unchanged at base-
line 39%), and no significant decrease in end-diastolic volumes
(260256 ml) and end-systolic volumes (158156 ml).
Discussion
The therapeutic potential of bone marrow cells has recently
been described in patients with acute MI [16]. However, no pre-
vious study analyzed the cause of interindividual differences
Figure 1AB. Responder to BMC therapy. Before BMC therapy, the imag-
es in the horizontal long axis (Figure 1A, top) and the polar maps (Figure
1B, top) showed Tc-99m-MIBI SPECT and F-18-FDG PET distribution
with the presence of an extensive nonviable myocardium (25% of total left
ventricle). At 3 months after BMC transplantation, horizontal long axis
slices (Figure 1A, bottom) and polar plots (Figure 1B, bottom) demon-
strated an improvement in perfusion and metabolism.
A
B
Figure 1C. Gated SPECT 3D images of endocardial surface silhouettes
at end-diastole and end-systole demonstrated post-transplantation im-
provement in LV function (see also the text in the case report 1).
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Figure 2AB. Non-responder to BMC therapy. Before BMC therapy, the
images in the horizontal long axis (Figure 2A, top) and the polar maps
(Figure 2B, top) showed very low MIBI and FDG uptake corresponding to
large nonviable myocardium (40% of total left ventricle). Horizontal long
axis slices (Figure 2A, bottom) and polar plots (Figure 2B, bottom) at 3
months after BMC transplantation demonstrated that the extent of nonvi-
able myocardium remained unchanged (38% of total left ventricle).
Figure 2C. Gated SPECT 3D images of endocardial surface silhouettes
at end-diastole and end-systole demonstrated no post-transplantation
improvement in LV function (see also the text in case report 2).
in the effectiveness of the cell therapy. First of all, it was absolutely
necessary to confirm correctly the presence of irreversible injury
in the left ventricular dysfunctional segments prior the cell thera-
py. The irreversible damage in this study has been identified
by dobutamine echocardiography and confirmed by radionuclide
imaging. It is generally accepted that in patients with ischemic
heart disease, contractile reserve has a lower sensitivity to detect
viable dysfunctional myocardium than myocardial perfusion SPECT
[9]. Metabolic imaging with F-18-FDG PET currently represents
the gold standard for myocardial tissue viability assessment with
higher sensitivity than perfusion imaging [10, 11].
The results obtained in the initial patients in this study (27 pa-
tients in the BMC treated group, 16 patients in the control group)
have been published previously [12]. Among the BMC group, we
identified 13 responders to therapy with average LVEF improve-
ment from 43.3% – 11% to 51.4% – 10.4% and EDV/ESV im-
provement from 145 ml/84 ml to 133 ml/67 ml. The remaining
14 patients were non-responders to therapy with no significant change
in LVEF (39.1% – 8.1% versus 39.8% – 7.4%) - the EDV/ESV
increased from 166 ml/105 ml to 188 ml/116 ml. For the identifica-
tion of responders and non-responders to cell transplantation, we
studied perfusion and metabolism characteristics of patients with
and without the benefit of BMC therapy. We used a polar map
with 10% decrements in MIBI uptake displayed in colour layers.
The level of minimum MIBI uptake in each infracted nonviable
region was determined. In case report 1 we demonstrated
a patient who was successfully treated by BMC transplantation.
Similarly to this patient, we observed prevailing MIBI uptake
in the range of 3150% of maximum in the dysfunctional segments
among other responders to therapy. In contrast, the patients with
very low MIBI uptake < 30% of maximum prevailed in the sub-
group of non-responders. In case report 2 we present a patient
without any benefit from BMC therapy with a typical example
of very low MIBI uptake.
In conclusion, we observed strong interindividual differences
in the effectiveness of cell therapy. Further studies with a larger
cohort of patients would be helpful to evaluate our findings. How-
ever, our preliminary results suggest that prevailing MIBI uptake
in the range of 3150% of maximum identified responders to the
cell therapy (supposedly those patients with the presence of at
least the minimum amount of myocytes with cell membrane in-
tegrity in the infarcted lesion). On the other hand, prevailing inf-
arction MIBI uptake in the range of 030% identified non-respon-
ders (those patients without any significant residual viability).
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